Výsledky vyhledávání - "Demi Niforos"

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

Autor: Muralidhar Beeram, Demi Niforos, Anna Spreafico, Julia Lester, Alison M. Paterson, Amita Patnaik, Alison M. Schram, Beth Bowers, Marco A. J. Iafolla, Marisa O. Peluso, Alison M. O'Neill, Jou-Ku Chung

Publikováno v: Journal of Clinical Oncology. 38:3064-3064

3064 Background: CD47 is a transmembrane protein that acts as a “Don’t Eat Me” signal to evade immune recognition. It is overexpressed in multiple cancer subtypes and is associated with poor prognosis. SRF231 is an investigational, fully human,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1b4bcb49f5e6a6fd383629fea90ae54
https://doi.org/10.1200/jco.2020.38.15_suppl.3064

Zobrazit plný text záznamu

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC)

Autor: Jonathan R. Strosberg, David Smith, John D. Carpten, Mark Marion Kowalski, Winnie S. Liang, Sarabjit Gahir, Ramesh K. Ramanathan, Michael J. Demeure, Tannaz Armaghany, Paul Fredlund, Samuel Ejadi, Andrew Dye, Shobana Sekar, Sean C. Semple, Aymen Elfiky, Demi Niforos, Timothy G. Whitsett

Publikováno v: Journal of Clinical Oncology. 34:2547-2547

2547Background: Polo-like kinase 1 (PLK1) regulates critical aspects of tumor progression. High expression levels correlate with poor survival in ACC. TKM-080301 is a lipid nanoparticle formulation of a siRNA against PLK1. Methods: TKM-080301 was eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2bddcdae5bee243070771ccdff45b43a
https://doi.org/10.1200/jco.2016.34.15_suppl.2547

Zobrazit plný text záznamu

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

Autor: Joycelyn Entwistle, Mark Marion Kowalski, Glen C. MacDonald, Wendy Chapman, Shauna Loewen, Jeannick Cizeau, Demi Niforos

Publikováno v: Drug Design, Development and Therapy

Mark Kowalski1, Joycelyn Entwistle2, Jeannick Cizeau2, Demi Niforos1, Shauna Loewen2, Wendy Chapman1, Glen C MacDonald21Viventia Biotechnologies Inc., Mississauga, ON, Canada; 2Viventia Biotechnologies Inc., Winnipeg, MB, CanadaPurpose: A Phase I dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7de4f558479bdb4182248a2d63c713
https://pubmed.ncbi.nlm.nih.gov/21151619

Zobrazit plný text záznamu

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Autor: Yan Xin, Lixin Shao, Wei Deng, Demi Niforos, Mark Kowalski, Linda M Bavisotto, Jun Kawashima, Susie Jun, Helen Collins, Srinivasan Ramanathan

Publikováno v: Blood. 122:1590-1590

Background Momelotinib (MMB, previously CYT387) is a selective small molecule inhibitor of JAK 1 and JAK 2 currently under investigation for the treatment of myelofibrosis (MF). Study CCL09101 is a Phase I/II, open-label, dose-escalation study of ora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::224683a2eba4a0140424b82c887e4f25
https://doi.org/10.1182/blood.v122.21.1590.1590

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání